Eli Lilly and Company has become a key player in the manufacturing of tirzepatide, a groundbreaking treatment for type 2 diabetes. Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates significant ability to improve glycemic control and reduce heart disease. The sophisticated synthesis of tirzepatide utilizes a series of precision steps